乌司奴单抗对银屑病患者血管炎症影响的IV期随机双盲安慰剂对照交叉研究(VIP-U试验)
本研究为IV期随机双盲安慰剂对照交叉试验,纳入43例中重度银屑病患者,评估乌司奴单抗对主动脉血管炎症(AVI)及炎症、脂质和糖代谢生物标志物的影响。第12周时,乌司奴单抗组AVI较安慰剂组降低18.65%(95%CI -29.45%至-7.85%),炎症生物标志物减少,载脂蛋白B脂蛋白升高。安慰剂组交叉后所有患者接受乌司奴单抗治疗52周,结束时AVI较基线无变化,炎症标志物持续降低,部分脂质指标和瘦素升高。
要点
- 乌司奴单抗治疗12周可降低中重度银屑病患者主动脉血管炎症。
- 52周治疗期间AVI较基线无变化,但炎症细胞因子持续降低。
- 乌司奴单抗治疗伴随载脂蛋白B脂蛋白和瘦素等代谢指标变化。
核心结论
- 阻断IL-12和/或IL-23可能短暂降低主动脉血管炎症,并对心血管疾病相关炎症细胞因子有更持久的降低作用。
研究设计与样本
- IV期随机双盲安慰剂对照交叉试验,共随机43例中重度银屑病患者。
主要发现
- 第12周时,乌司奴单抗组AVI降低18.65%(95%CI -29.45%至-7.85%),炎症生物标志物减少,载脂蛋白B脂蛋白升高。
- 第12周后安慰剂组交叉,所有患者接受乌司奴单抗治疗52周。
- 52周乌司奴单抗治疗结束时,AVI较基线无变化,炎症标志物降低,部分脂质指标和瘦素升高。
临床怎么用
- 乌司奴单抗治疗中重度银屑病可短暂降低主动脉血管炎症,并持续降低心血管相关炎症细胞因子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a T helper type 17 autoimmune disease associated with an increased risk cardiovascular events and mortality. Ustekinumab, an antibody to p40, blocks cytokines IL-12 and IL-23, and is a highly effective and safe treatment for psoriasis. We conducted a randomized double-blinded placebo-controlled trial to determine the effect of ustekinumab on aortic vascular inflammation (AVI) measured by imaging, and key biomarkers of inflammation, lipid, and glucose metabolism in the blood of patients with moderate-to-severe psoriasis. A total of 43 patients were randomized, and at week 12, ustekinumab-treated patients had a -18.65% (95% confidence interval = -29.45% to -7.85%) reduction in AVI, a reduction in inflammatory biomarkers, and an increase in apolipoprotein B lipoproteins compared with placebo. At week 12, placebo patients were crossed over such that all patients received ustekinumab for 52 weeks. At the end of 52 weeks of ustekinumab treatment, there was no change in AVI compared with baseline, inflammatory markers were reduced, and there were increases in selected measures of lipids and leptin. These results show that blockade of IL-12 and/or IL-23 may transiently reduce AVI, with more durable reduction in inflammatory cytokines associated with cardiovascular disease.
引用
- Gelfand JM, Shin DB, Alavi A, et al. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). J Invest Dermatol. 2019. PMID: 31326395. doi:10.1016/j.jid.2019.07.679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。